Compounded weight loss medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have been a popular and cost-effective alternative for many patients. However, recent FDA regulations will soon restrict access to compounded GLP-1 medications due to the resolution of prior shortages.
At Vive Aesthetics & Wellness, we’re committed to keeping our patients informed. This blog will help you understand the FDA’s decision, how it affects your treatment, and what steps you should take next to ensure a seamless transition in your weight loss journey.
In this blog, we’ll discuss everything you need to know about CoolSculpting Elite in Marlton, NJ including how it works, the treatment process, and how you can achieve long-lasting body contouring results.
Understanding GLP-1 Weight Loss Medications
What are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) receptor agonists like semaglutide and tirzepatide work by:
- Regulating blood sugar and insulin levels
- Reducing appetite and cravings
- Slowing digestion for long-lasting fullness
- Helping the body burn fat more efficiently
These medications were originally developed for diabetes management but have been widely prescribed for medical weight loss in Marlton, NJ, due to their proven effectiveness in reducing body weight.
Why is the FAD Restricting Compounded Semaglutide & Tirzepatide?
The Impact of FDA Drug Shortage Regulations
Compounded versions of GLP-1 medications became widely used during shortages of brand-name weight loss injections like Ozempic, Wegovy, Mounjaro, and Zepbound.
Now that pharmaceutical manufacturers have resolved these shortages, the FDA has removed these drugs from the U.S. shortage list, meaning compounded versions will soon be discontinued.
Key FDA Updates:
- Tirzepatide (Mounjaro, Zepbound) was removed from the shortage list on October 2, 2024
- Semaglutide (Ozempic, Wegovy) was removed from the shortage list on February 21, 2025
Under FDA regulations, once a medication is no longer in shortage, compounding pharmacies must stop producing it.
Important FDA Deadlines for Compounded GLP-1 Medications
If you’re currently using compounded semaglutide or tirzepatide, here are the key dates to know:
Compounded Semaglutide (Ozempic, Wegovy) Availability
- April 22, 2025 – State-licensed compounding pharmacies (503A) must stop production
- May 22, 2025 – Outsourcing facilities (503B) must stop production
Compounded Tirzepatide (Mounjaro, Zepbound) Availability
- February 18, 2025 – State-licensed compounding pharmacies (503A) already stopped production
- March 19, 2025 – Outsourcing facilities (503B) must stop production
Next Steps for Vive Patients
Refill While You Can: With FDA deadlines approaching, we strongly recommend that patients who rely on compounded GLP-1 medications schedule a refill now before access is restricted.
Explore FDA-Approved Alternatives: Once compounded versions are discontinued, patients will need to transition to brand-name weight loss injections such as:
- Ozempic & Wegovy (Semaglutide)
- Mounjaro & Zepbound (Tirzepatide)
At Vive Aesthetics & Wellness, our team will work with you to determine the best treatment options moving forward so you can stay on track with your weight loss goals.
Meet With a Weight Loss Specialist
If you have questions or concerns about your treatment plan, we highly recommend booking a consultation to discuss your options. Our medical weight loss specialists in Marlton, NJ are here to ensure you receive personalized care and the best possible results.
Why Choose Vive Aesthetics & Wellness for Medical Weight Loss in Marlton, NJ?
- Experienced Weight Loss Specialists – Our team offers expert GLP-1 weight loss guidance tailored to your unique needs.
- Personalized Plans – We customize each treatment plan for long-term success and sustainable weight loss.
- Science-Backed Treatments – We stay up-to-date with the latest advancements in medical weight loss solutions for optimal patient results.
Questions? Call us at 856-988-8483 or click below to book your consultation.
Treatment Planning Tool Schedule a Consultation
Final Thoughts
The FDA’s restrictions on compounded GLP-1 medications mark a significant shift in the weight loss industry, but Vive is here to guide you every step of the way. If you’re currently using compounded semaglutide or tirzepatide, now is the time to refill your prescription and plan for the future.
Don’t wait – schedule your consultation today!
